TG Therapeutics (NASDAQ:TGTX) Announces Earnings Results

TG Therapeutics (NASDAQ:TGTX) posted its quarterly earnings data on Monday. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07, Zacks reports. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The company had revenue of $108.19 million during the quarter, compared to analysts’ expectations of $100.67 million.

TG Therapeutics Stock Performance

Shares of TGTX stock opened at $34.42 on Tuesday. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a market capitalization of $5.36 billion, a PE ratio of -344.17 and a beta of 2.26. TG Therapeutics has a 52-week low of $12.93 and a 52-week high of $36.84. The stock’s 50-day moving average price is $30.79 and its 200 day moving average price is $28.24.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on TGTX shares. StockNews.com downgraded TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 31st. HC Wainwright reissued a “buy” rating and issued a $55.00 target price on shares of TG Therapeutics in a research note on Wednesday, January 15th. JPMorgan Chase & Co. increased their price objective on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, The Goldman Sachs Group boosted their price target on TG Therapeutics from $20.00 to $22.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $40.67.

Insider Activity

In other TG Therapeutics news, CFO Sean A. Power sold 10,021 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the completion of the transaction, the chief financial officer now directly owns 660,611 shares in the company, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 10.50% of the company’s stock.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.